CoTherix Signs R&D Agreement

CoTherix Inc. signed a research and development deal to seek an extended-release version of an inhaled drug with Quadrant Drug Delivery Ltd., it said Tuesday. South San Francisco-based CoTherix did not disclose the financial terms of the deal with Quadrant, a privately held British company with its head office in Nottingham. The research covers Ventavis, a CoTherix drug used to treat pulmonary arterial hypertension, or PAH, which the company said affects 50,000 people in the United States, though only 15,000 of them have been diagnosed. The cause of the disease, which can kill its victims, is not known.

San Francisco Business Times (http://www.bizjournals.com/sanfrancisco/stories/2005/04/04/daily16.html)